IgA nephropathy affects 25-50 per million annually, with 20–40% progressing to end-stage kidney disease. Diagnosed cases in the US are expected to reach 135,000 by 2030. Treatments include
ACE inhibitors
○
Search Drug
,
ARBs
○
Search Drug
,
corticosteroids
○
Search Drug
, and
immunosuppressants
○
Search Drug
. FDA-approved treatments are TARPEYO,
FILSPARI
○
Search Drug
, and
FABHALTA
○
Search Drug
. The IgA nephropathy market is projected to reach ~USD 4.1 billion by 2034, driven by novel therapies like
Novartis
○
Search Organization
’
Atrasentan
○
Search Drug
, Otsuka/
Visterra
○
Search Organization
’s
Sibeprenlimab
○
Search Drug
, Vertex/Alpine’s
Povetacicept
○
Search Drug
, and others.